Drugs / MCV4-TT
last change Apr 2020 re-read 2 minutes ago

MCV4-TT

Vaccine

Developed for
meningococcal meningitis

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03205358 Comparator Mar → Aug 2015 meningococcal meningitis Sanofi Pasteur, a Sanofi Company Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MCV4-TT “versus a licensed conjugate vaccine MCV4-TT (NCT03205358)” PMID 32233959 Apr 2020
Modality Vaccine “licensed conjugate vaccine MCV4-TT” PMID 32233959 Apr 2020
Route Intramuscular “0.5 mL, IM” NCT03205358